Shandong Weigao Blood - Public Comps and Valuation Multiples

Shandong Weigao Blood Overview

About Shandong Weigao Blood

Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.

Founded

2004

HQ

Employees

n/a

Website

wego-healthcare.com

Sectors

Medical Supplies

Financials

Last FY Revenue $505M

Last FY EBITDA $110M

EV

$1.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Shandong Weigao Blood Financials

See Shandong Weigao Blood valuation multiples based on analyst estimates

Shandong Weigao Blood P&L

In the most recent fiscal year, Shandong Weigao Blood reported revenue of $505M and EBITDA of $110M.

Shandong Weigao Blood expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Shandong Weigao Blood valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$505M	XXX	XXX	XXX
Gross Profit	XXX	$214M	XXX	XXX	XXX
Gross Margin	XXX	42%	XXX	XXX	XXX
EBITDA	XXX	$110M	XXX	XXX	XXX
EBITDA Margin	XXX	22%	XXX	XXX	XXX
EBIT	XXX	$78.0M	XXX	XXX	XXX
EBIT Margin	XXX	15%	XXX	XXX	XXX
Net Profit	XXX	$63.0M	XXX	XXX	XXX
Net Margin	XXX	12%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Shandong Weigao Blood including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Shandong Weigao Blood achieved $505M in revenue and $110M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$505M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$214M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	42.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$110M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	21.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$78.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	15.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$63.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	12.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Shandong Weigao Blood

This financial data table provides comprehensive performance metrics for Shandong Weigao Blood, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Shandong Weigao Blood reported $505M in total revenue.
Fiscal year EBITDA was $110M.
The company maintained a gross profit margin of 42.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 21.9%.
Net profit margin reached 12.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Shandong Weigao Blood. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Shandong Weigao Blood Stock Performance

Shandong Weigao Blood has current market cap of CNY 15.8B (or $2.2B), and EV of CNY 13.6B (or $1.9B).

Market Cap Evolution

Shandong Weigao Blood Stock Data

As of October 3, 2025, Shandong Weigao Blood's stock price is CNY 39 (or $5).

See Shandong Weigao Blood trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.9B	$2.2B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Shandong Weigao Blood Valuation Multiples

Shandong Weigao Blood's trades at 3.8x EV/Revenue multiple, and 17.2x EV/EBITDA.

See valuation multiples for Shandong Weigao Blood and 15K+ public comps

Shandong Weigao Blood Financial Valuation Multiples

As of October 3, 2025, Shandong Weigao Blood has market cap of $2.2B and EV of $1.9B.

Equity research analysts estimate Shandong Weigao Blood's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Shandong Weigao Blood's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.2B	XXX	$2.2B	XXX	XXX	XXX
EV (current)	$1.9B	XXX	$1.9B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	3.8x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	17.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	24.4x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	35.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	34.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Shandong Weigao Blood Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Shandong Weigao Blood Margins & Growth Rates

Shandong Weigao Blood's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Shandong Weigao Blood's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shandong Weigao Blood's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Shandong Weigao Blood and other 15K+ public comps

Shandong Weigao Blood Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	22%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	27%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial